117 related articles for article (PubMed ID: 26394902)
21. Insights into reasons for discontinuation according to year of starting first regimen of highly active antiretroviral therapy in a cohort of antiretroviral-naïve patients.
Cicconi P; Cozzi-Lepri A; Castagna A; Trecarichi EM; Antinori A; Gatti F; Cassola G; Sighinolfi L; Castelli P; d'Arminio Monforte A;
HIV Med; 2010 Feb; 11(2):104-13. PubMed ID: 19732176
[TBL] [Abstract][Full Text] [Related]
22. Switch from a first virologically effective protease inhibitor-containing regimen to a regimen containing efavirenz, nevirapine or abacavir.
Abgrall S; Yeni PG; Bouchaud O; Costagliola D;
AIDS; 2006 Oct; 20(16):2099-106. PubMed ID: 17053356
[TBL] [Abstract][Full Text] [Related]
23. Cost-effectiveness analysis of emtricitabine/tenofovir versus lamivudine/zidovudine, in combination with efavirenz, in antiretroviral-naive, HIV-1-infected patients.
Sánchez-de la Rosa R; Herrera L; Moreno S
Clin Ther; 2008 Feb; 30(2):372-81. PubMed ID: 18343275
[TBL] [Abstract][Full Text] [Related]
24. Adherence among rural HIV-infected patients in the deep south: a comparison between single-tablet and multi-tablet once-daily regimens.
Tennant SJ; Hester EK; Caulder CR; Lu ZK; Bookstaver PB
J Int Assoc Provid AIDS Care; 2015; 14(1):64-71. PubMed ID: 25331217
[TBL] [Abstract][Full Text] [Related]
25. Comparison of genotypic resistance profiles and virological response between patients starting nevirapine and efavirenz in EuroSIDA.
Bannister WP; Ruiz L; Cozzi-Lepri A; Mocroft A; Kirk O; Staszewski S; Loveday C; Karlsson A; Monforte Ad; Clotet B; Lundgren JD;
AIDS; 2008 Jan; 22(3):367-76. PubMed ID: 18195563
[TBL] [Abstract][Full Text] [Related]
26. Effectiveness of antiretroviral therapy in individuals who for economic reasons were switched from a once-daily single-tablet regimen to a triple-tablet regimen.
Engsig FN; Gerstoft J; Helleberg M; Nielsen LN; Kronborg G; Mathiesen LR; Obel N
J Acquir Immune Defic Syndr; 2014 Aug; 66(4):407-13. PubMed ID: 24984188
[TBL] [Abstract][Full Text] [Related]
27. Cost-effectiveness of efavirenz vs rilpivirine in HIV patients initiating first-line combination antiretroviral therapy.
Bonafede M; Juday T; Lenhart G; Pan K; Hebden T; Correll T
J Med Econ; 2013; 16(4):552-9. PubMed ID: 23391157
[TBL] [Abstract][Full Text] [Related]
28. Switch to efavirenz (EFV) after protease-inhibitor (PI)-failure: explorative analysis of outcome by baseline viral VS tolerability failure.
Khaykin P; Postel N; Reeb I; Staszewski S
Eur J Med Res; 2008 Apr; 13(4):169-72. PubMed ID: 18504172
[TBL] [Abstract][Full Text] [Related]
29. Cost analysis of initial highly active antiretroviral therapy regimens for managing human immunodeficiency virus-infected patients according to clinical practice in a hospital setting.
Colombo GL; Castagna A; Di Matteo S; Galli L; Bruno G; Poli A; Salpietro S; Carbone A; Lazzarin A
Ther Clin Risk Manag; 2014; 10():9-15. PubMed ID: 24379676
[TBL] [Abstract][Full Text] [Related]
30. Interpreting the reasons for the choice and changing of two drug regimens in an observational cohort: comparison of a ritonavir-boosted protease inhibitor-based versus a nonnucleoside reverse transcriptase inhibitor-based first-line regimen.
Jarrin I; Hernández-Novoa B; Alejos B; Santos I; Lopez-Aldeguer J; Riera M; Gutiérrez F; Rubio R; Antela A; Blanco JR; Moreno S;
HIV Med; 2014 Oct; 15(9):547-56. PubMed ID: 24655804
[TBL] [Abstract][Full Text] [Related]
31. Absence of a relation between efavirenz plasma concentrations and toxicity-driven efavirenz discontinuations in the EuroSIDA study.
van Luin M; Bannister WP; Mocroft A; Reiss P; Di Perri G; Peytavin G; Molto J; Karlson A; Castagna A; Beniowski M; Lundgren JD; Burger DM;
Antivir Ther; 2009; 14(1):75-83. PubMed ID: 19320239
[TBL] [Abstract][Full Text] [Related]
32. Odds of Viral Suppression by Single-Tablet Regimens, Multiple-Tablet Regimens, and Adherence Level in HIV/AIDS Patients Receiving Antiretroviral Therapy.
Sutton SS; Magagnoli J; Hardin JW
Pharmacotherapy; 2017 Feb; 37(2):204-213. PubMed ID: 28028855
[TBL] [Abstract][Full Text] [Related]
33. Cost-effectiveness of DTG + ABC/3TC versus EFV/TDF/FTC for first-line treatment of HIV-1 in the United States.
Peng S; Tafazzoli A; Dorman E; Rosenblatt L; Villasis-Keever A; Sorensen S
J Med Econ; 2015; 18(10):763-76. PubMed ID: 25934146
[TBL] [Abstract][Full Text] [Related]
34. Randomized open-label trial of two simplified, class-sparing regimens following a first suppressive three or four-drug regimen.
Fischl MA; Collier AC; Mukherjee AL; Feinberg JE; Demeter LM; Tebas P; Giuliano M; Dehlinger M; Garren K; Brizz B; Bassett R
AIDS; 2007 Jan; 21(3):325-33. PubMed ID: 17255739
[TBL] [Abstract][Full Text] [Related]
35. Effectiveness and safety of generic fixed-dose combination of tenofovir/emtricitabine/efavirenz in HIV-1-infected patients in Western India.
Pujari S; Dravid A; Gupte N; Joshi K; Bele V
Medscape J Med; 2008; 10(8):196. PubMed ID: 18924648
[TBL] [Abstract][Full Text] [Related]
36. Comparing the effectiveness of efavirenz and nevirapine for first-line antiretroviral therapy in a South African multicentre cohort.
Bock P; Fatti G; Grimwood A
Int Health; 2013 Jun; 5(2):132-8. PubMed ID: 24030113
[TBL] [Abstract][Full Text] [Related]
37. Compact quadruple therapy with the lamivudine/zidovudine combination tablet plus abacavir and efavirenz, followed by the lamivudine/zidovudine/abacavir triple nucleoside tablet plus efavirenz in treatment-naïve HIV-infected adults.
Ruane PJ; Parenti DM; Margolis DM; Shepp DH; Babinchak TJ; Van Kempen AS; Kauf TL; Danehower SA; Yau L; Hessenthaler SM; Goodwin D; Hernandez JE;
HIV Clin Trials; 2003; 4(4):231-43. PubMed ID: 12916008
[TBL] [Abstract][Full Text] [Related]
38. Adherence and persistence with non-nucleoside reverse transcriptase inhibitor-based antiretroviral regimens.
Taneja C; Juday T; Gertzog L; Edelsberg J; Correll T; Hebden T; Oster G
Expert Opin Pharmacother; 2012 Oct; 13(15):2111-8. PubMed ID: 22970926
[TBL] [Abstract][Full Text] [Related]
39. Reasons and Risk Factors for the Initial Regimen Modification in Chinese Treatment-Naïve Patients with HIV Infection: A Retrospective Cohort Analysis.
Sun J; Liu L; Shen J; Qi T; Wang Z; Song W; Zhang R; Lu H
PLoS One; 2015; 10(7):e0133242. PubMed ID: 26207639
[TBL] [Abstract][Full Text] [Related]
40. Lopinavir/ritonavir or efavirenz plus two nucleoside analogues as first-line antiretroviral therapy: a non-randomized comparison.
De Luca A; Cozzi-Lepri A; Antinori A; Zaccarelli M; Bongiovanni M; Di Giambenedetto S; Marconi P; Cicconi P; Resta F; Grisorio B; Ciardi M; Cauda R; Monforte Ad; ; ; ;
Antivir Ther; 2006; 11(5):609-18. PubMed ID: 16964829
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
